Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694790 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6KMT2AMAOB | |
| SCHEMBL3688386 | 0.83 | CYP3A4 (0.56) | CYP3A4CYP1A2CYP2D6MAOBSMN1; SMN2 | |
| SCHEMBL3688385 | 0.83 | CYP3A4 (0.56) | CYP3A4CYP1A2CYP2D6MAOBSMN1; SMN2 | |
| SCHEMBL3696868 | 0.80 | BCHE (0.48) | CYP3A4CYP1A2CYP2D6SMN1; SMN2BCHE | |
| SCHEMBL3687879 | 0.80 | BCHE (0.48) | CYP3A4CYP1A2CYP2D6SMN1; SMN2BCHE | |
| SCHEMBL22978784 | 0.80 | CYP3A4 (0.40) | CYP3A4CYP1A2CYP2D6MAOBSMN1; SMN2 | |
| SCHEMBL29117238 | 0.79 | CHRM5 (0.46) | CYP3A4CYP1A2CYP2D6MAOBSMN1; SMN2 | |
| SCHEMBL29117242 | 0.79 | CHRM5 (0.46) | CYP3A4CYP1A2CYP2D6MAOBSMN1; SMN2 | |
| SCHEMBL29042805 | 0.78 | CHRNB2 (0.41) | CYP3A4CYP1A2CYP2D6MAOBSMN1; SMN2 | |
| SCHEMBL14530201 | 0.77 | PIK3CD (0.40) | CYP3A4CYP1A2CYP2D6KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331546-A1 | METHOD FOR OPTICAL RESOLUTION OF ALKYL PIPERIDIN-3-YL CARBAMATE AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2248803-A1 | METHOD FOR OPTICAL RESOLUTION OF ALKYLPIPERIDIN-3-YL CARBAMATE AND INTERMEDIATE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331546-A1 | METHOD FOR OPTICAL RESOLUTION OF ALKYL PIPERIDIN-3-YL CARBAMATE AND INTERMEDIATE THEREFOR | FAR1, NOTUM, CYP51A1 | CYP3A4 632/4885CYP1A2 3943/4885CYP2D6 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.